Mpox

Clinical Resources

Important information about mpox vaccination

Jynneos vaccine is recommended for adults age 18 years and older at risk for mpox. See the current CDC Recommended Adult Immunization Schedule for details.

FDA Emergency Use Authorization (EUA) permits the use of Jynneos vaccine for children younger than age 18 years determined to be at high risk for mpox.

The preferred route of administration for Jynneos vaccine is subcutaneous.

Materials for Providers

Alphabetical by Title

Standing Orders for Administering Jynneos (Mpox) Vaccine by Subcutaneous Injection to Persons 18 Years of Age and Older [CDC]

Vaccine Storage and Handling Toolkit: Mpox Vaccines Addendum [CDC]

CDC guidance on proper storage and handling of mpox vaccines.

CDC · FDA · State

ACIP Recommendations

Current Recommendations

Use of Jynneos (smallpox and monkeypox vaccine, live, nonreplicating) for preexposure vaccination of persons at risk for occupational exposure to orthopoxviruses: Recommendations of the Advisory Committee on Immunization Practices — US, 2022
MMWR, May 27, 2022, Vol 71

Additional Federal Resources

ACIP

General Mpox Information

CDC Mpox Vaccination Guidance

Vaccine Administration, Storage and Handling

Additional Resources

Vaccine Information Statements

Smallpox/monkeypox VIS
Updated: November 14, 2022

FDA Package Inserts & EUAs

Smallpox & Mpox: ACAM2000 Package Insert
Emergent Biosolutions
Smallpox & Mpox: Jynneos Package Insert
Bavarian Nordic A/S

Travel

All travelers should be up to date on routine vaccines. Depending on the destination, itinerary, and duration of travel, additional vaccines may be recommended.

CDC Resources

Mpox travel information

Partner Resources

Non-Governmental

Manufacturers

More from Immunize.org

This page was updated on .